Jonathan Behr
QuietNamed in filings at SV Life Sciences
- Board seats filed
- 6
all filings on record
Named in filings at SV Life Sciences
all filings on record
last 24 months
from a verified or cited source
| Violet Therapeutics | Biotech & pharma | April 2023 | Partners Innovation |
| Endlyz Therapeutics | Biotech & pharma | July 2021 | None on file |
| QurAlis | Biotech & pharma | May 2020 | Adams Street, Polaris Partners |
| NITROME BIOSCIENCES | Not yet classified | April 2020 | None on file |
| ImmunoMolecular Therapeutics | Biotech & pharma | June 2019 | BCV |
| Veralox Therapeutics | Not yet classified | May 2019 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Jonathan Behr on the board, based on 4 filed seats with a verified or cited source.
2 more filed seats not yet classified, left out of the shares above.